Evidence map›Paper›PMID 40361237›Full record

ArticleJournal of cheminformatics2025

Generating diversity and securing completeness in algorithmic retrosynthesis.

Florian Mrugalla, Christopher Franz, Yannic Alber, Georg Mogk, Martín Villalba, Thomas Mrziglod, Kevin Schewior

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Florian MrugallaBayer AG, Leverkusen, Germany. florian.mrugalla@bayer.com.
Christopher Franz, Frankfurt, Germany.
Yannic AlberBayer AG, Leverkusen, Germany.
Georg MogkBayer AG, Leverkusen, Germany.
Martín Villalba, Cologne, Germany.
Thomas MrziglodBayer AG, Leverkusen, Germany.
Kevin SchewiorDepartment of Mathematics and Computer Science, University of Cologne, Cologne, Germany.

Funding

Danmarks Frie Forskningsfond DFF-0135-00018B
6 · The paper itself

Abstract

Chemical synthesis planning has considerably benefited from advances in the field of machine learning. Neural networks can reliably and accurately predict reactions leading to a given, possibly complex, molecule. In this work we focus on algorithms for assembling such predictions to a full synthesis plan that, starting from simple building blocks, produces a given target molecule, a procedure known as retrosynthesis. Objective functions for this task are hard to define and context-specific. In order to generate a diverse set of synthesis plans for chemists to select from, we capture the concept of diversity in a novel chemical diversity score (CDS). Our experiments show that our algorithm outperforms the algorithm predominantly employed in this domain, Monte-Carlo Tree Search, with respect to diversity in terms of our score as well as time efficiency. SCIENTIFIC CONTRIBUTION: We adapt Depth-First Proof-Number Search (DFPN) (Please refer to https://github.com/Bayer-Group/bayer-retrosynthesis-search for the accompanying source code.) and its variants, which have been applied to retrosynthesis before, to produce a set of solutions, with an explicit focus on diversity. We also make progress on understanding DFPN in terms of completeness, i.e., the ability to find a solution whenever there exists one. DFPN is known to be incomplete, for which we provide a much cleaner example, but we also show that it is complete when reinforced with a threshold-controlling routine from the literature.

Indexed as

Chemical diversity scoreComputer-Assisted Synthesis Planning (CASP)DFPNRetrosynthesis

Identifiers

PMID40361237
PMCPMC12076909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.